MBBS, MD, MBA (NYU-Stern, Finance): worked/did research at Cornell and Harvard Affiliated Hospitals
Portfolio Manager/founder for own US biotech/pharma-focused asset management firm, Vasuda Capital Management.
Founder/Editor: Vasuda Healthcare Analytics: SA Marketplace premium biotech/pharma research service
Founder and Sponsor: Vasuda Global Orphan/Rare Diseases Index, first global equity index representing the orphan/rare disease sector (vasudaindices.com), index calculator=Solactive A.G. https://www.vasudaindices.com
Edwin Kye is a junior economics major at Cornell University. He has advised analysts and executives at various hedge funds and asset management firms about the sportswear industry and is a four-star analyst per TipRanks, placing him in the top fifth of financial bloggers and analysts as measured by predictive performance. Please feel to reach out at email@example.com.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Pioneer of the PROVEN trading system BAD BEAT INVESTING, Quad 7 Capital, (parent company of Quad 7 Research, Quad 7 Partners, and Quad 7 Poker), was founded in 2017 by a team that consists of a long time investor, health researcher, financial author, professor, professional poker player, and politician. The BAD BEAT Investing Service is a top performer, focused on extreme value, and leveraging news driven events for rapid return swing trades.
The company has expertise in business, policy, economics, mathematics, game theory and the sciences. The company has experience with government, academia, and private industry. Quad7Capital.com covers a wide range of sectors and companies, with particular emphasis on news related items and mini-analyses on growth companies, cryptocurrencies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies. It further offers money saving tips and market news.
Quad 7 Partners is the driving force behind the overall focus on current events, earnings, and timely developments, while Quad 7 Research aims to conduct several in depth analyses per month to identify misplaced market bets, and deep value situations. We are on Stocktwits, and Twitter under username _Quad7Capital_, and on Facebook and TalkMarkets under Quad7Capital.
My goal is to help young people get ahead in investing.
Active > Passive.
Please note that the article that you are reading here was originally written on my blog and is republished in Seeking Alpha and other forums. Consequently, I neither track nor respond to comments here. I am sorry! ================ Editors' Note: Seeking Alpha monitors Dr. Damodaran blog and posts relevant articles on his behalf.
I managed a long only equity portfolio belonging to a student investment club worth $170K for 2 years. Currently part of the analyst team for an early stage venture capital firm while managing my own portfolio.
My focus is in biotech and healthcare stocks, especially small cap GARP stocks. I do not time my articles to coincide with a good buy point for the stock. Rather, my job is to uncover the company, analyze its products, pipeline, and also the industry trend.
I'm open for potential collaboration and looking forward to advance my career in investment related fields.
Charlie Bilello is the Director of Research at Pension Partners, LLC, an investment advisor that manages mutual funds and separate accounts. He is the co-author of four award-winning research papers on market anomalies and investing. Mr. Bilello is responsible for strategy development, investment research and communicating the firm’s investment themes and portfolio positioning to clients. Prior to joining Pension Partners, he was the Managing Member of Momentum Global Advisors and previously held positions as a Credit, Equity and Hedge Fund Analyst at billion dollar alternative investment firms.
Mr. Bilello holds a J.D. and M.B.A. in Finance and Accounting from Fordham University and a B.A. in Economics from Binghamton University. He is a Chartered Market Technician (CMT) and also holds the Certified Public Accountant (CPA) certificate.
In 2017, Charlie was named the StockTwits Person of the Year. He is a frequent contributor to Yahoo Finance and has been interviewed on CNBC, Bloomberg, and Fox Business.
SA PRO author & marketplace contributor. Successful PRO calls include $AKAO (+400% within 6 months) & $MRNS (+450% within 6 months).
I am providing members of my marketplace service, 'Second-Level Investing' with exclusive ideas, analysis and interviews with managers and subject matter experts.
- A former diplomat & entrepreneur. A former Project Manager at UN Principles for Responsible Investment
- An alumni of SciencesPo Paris
- Based in Luxembourg
Author of INTRODUCTIION TO FINANCIAL ACCOUNTING @ $2.99 for the e-book (http://booklocker.com/books/9608.html), MANAGERIAL ACCOUNTING @ $2.99 for the e-book (http://booklocker.com/books/9631.html), THE CANNABIS REPORT (weekly on http://investorshub.advfn.com/) & MARIJUANA STOCKS (http://booklocker.com/books/9045.html).
Accounting Professor teaching financial accounting; PhD, CPA, CMA, CGMA. He holds a BSBA from the University of Arizona, a Macc. from the University of Arizona, and his PhD from Virginia Tech. He worked in public accounting, industry, as a CFO, a government auditor for the California Auditor General and in litigation support. His publications have been used and filed in Court proceedings by the Securities and Exchange Commission, he has been quoted in the Wall Street Journal, and his background includes litigation support and expert testimony in cases involving business litigation (e.g., Ford, GM, and so on) in CA, AZ, TX, NV and MN. He enjoys trading stocks and securities, teaching his classes, and publishing in related areas. Also home repair and remodel, snorkling, and cruises to the Carribean.
Avi Gilburt is founder of ElliottWaveTrader.net, a live trading room and member forum focusing on Elliott Wave market analysis with over 3000 members and over 450 money manager clients. Avi emphasizes a comprehensive reading of charts and wave counts that is free of personal bias or predisposition.
Avi is an accountant and a lawyer by training. His education background includes his graduating college with dual accounting and economics majors, and he then passed all four parts of the CPA exam at once right after he graduated college. He then earned his Juris Doctorate in an advanced two and a half year program at the St. John’s School of Law in New York, where he graduated cum laude, and in the top 5% of his class. He then went onto the NYU School of Law for his masters of law in taxation (LL.M.).
Before retiring from his legal career, Avi was a partner and National Director at a major national firm. During his legal career, he spearheaded a number of acquisition transactions worth hundreds of millions to billions of dollars in value. So, clearly, Mr. Gilburt has a detailed understanding how businesses work and are valued.
Yet, when it came to learning how to accurately analyze the financial markets, Avi had to unlearn everything he learned in economics in order to maintain on the correct side of the market the great majority of the time. In fact, once he came to the realization that economics and geopolitics fail to assist in understanding how the market works, it allowed him to view financial markets from a more accurate perspective.
For those interested in how Avi went from a successful lawyer and accountant to become the founder of Elliottwavetrader.net, his detailed story is linked here.
Since Avi began providing his analysis to the public, he has made some spectacular market calls which has earned him the reputation of being one of the best technical analysts in the world.
As an example of some of his most notable astounding market calls, in July of 2011, he called for the USD to begin a multi-year rally from the 74 region to an ideal target of 103.53. In January of 2017, the DXY struck 103.82 and began a pullback expected by Avi.
As another example of one of his astounding calls, Avi called the top in the gold market during its parabolic phase in 2011, with an ideal target of $1,915. As we all know, gold hit a high of $1,921, and pulled back for over 4 years since that time. The night that gold hit its lows in December of 2015, Avi was telling his subscribers that he was on the phone with his broker buying a large order of physical gold, while he had been accumulating individual miner stocks that month, and had just opened the EWT Miners Portfolio to begin buying individual miners stocks due to his expectation of an impending low in the complex.
One of his most shocking calls in the stock market was his call in 2015 for the S&P500 to rally from the 1800SPX region to the 2600SPX region, whereas it would coincide with a “global melt-up” in many other assets. Moreover, he was banging on the table in November of 2016 that we were about to enter the most powerful phase of the rally to 2600SPX, and he strongly noted that it did not matter who won the 2016 election in the US, despite many believing that the market would “crash” if Trump would win the election. This was indeed a testament to the accuracy of the Fibonacci Pinball method that Avi developed.
ARK Invest holds a precision lens on thematic investing. We focus on disruptive innovation and identify themes that will enhance productivity and create wealth. ARK seeks to research and invest in technologically enabled innovation that cuts across economic sectors and changes the way our world works. Our current themes include: Industrial Innovation, Web x.0, and the Genomic Revolution. Innovation is inevitable, and ultimately wins out in an equity market.
Our research is made available on our website and we invite everyone to participate in our discussions around thematic investing in innovation. For more information please visit: http://ark-invest.com
Sirius capital is a Life Science consultancy firm providing guidance to investors and entrepreneurs in private and publicly traded companies. The managers are Mr. Dror Ozeri, CPA. Adv. and Dr. Ariel Kamsler PhD who combine their extensive experience in Pharma and drug development with financial management expertise.
Steven H. Goldman is a commercial litigation lawyer and senior partner in the Toronto law firm of Goldman Hine LLP. Steven graduated with a B.A., President's Medal recipient (1976, Carleton University, Ottawa, Ontario) and J.D. (1980, Queen's University, Kingston, Ontario). He is a former member of the board of directors of Tribute Pharmaceuticals Inc., a Canadian public pharmaceutical company which recently merged with Pozen Pharmaceuticals on February 5, 2016, and now known as Aralez Pharmaceuticals (Nasdaq: ARLZ). He is currently a member of the board of directors of both Comstock Metals Ltd. (TSX.V: CSL.V) and Select Sands Corp. (TSX.Venture: SNS.V and OTCQX: SLSDF). Steven is a member of the Executive of the Ontario Bar Association, Franchise Law Section as well as the American Bar Association, Franchise Forum (Associate Member). Steven was President & CEO of Speedy AutoService and Minute Muffler from December 2007 to December 31, 2009 (with approximately 160 locations across Canada).
Former financial analyst - CFA (inactive), portfolio manager and research director with over forty years of investment experience. Media credentials/experience includes daily radio commentaries, weekly newspaper columnist and Internet video host. Also a published business/financial markets author.
HIT THE FOLLOW TAB AND KEEP UP WITH ALL OF OUR ARTICLES! and Remember To
“Never Give Up, Never Ever Give Up”
A lifelong student of the markets, speculator, and investor, decades of experience have forged Adam into a hardcore contrarian. He believes in buying low when others are afraid, then later selling high when others are brave. He founded the financial-market research company Zeal LLC, and continues to write acclaimed weekly and monthly subscription newsletters.
I have been a successful private investor in the market for the last 20 years. My focus was mostly on Tech/Internet when I started, but about 15 years ago I became extremely interested in the Gold and Silver sector as I anticipated a major bull run.
My in-depth research on gold and silver companies began during 2003 or so, and it has been a consistent passion since that time. I'm familiar with their stories, their stock patterns, their highs and lows, their operations/projects, their successes and failures, their management teams and turnover at the top, and all other facets of these precious metal companies.
This sector has been my singular focus since I started sharing my ideas on Seeking Alpha back in 2014, as I anticipated that gold and silver would soon be bottoming out and a massive bull market would unfold. That has started to occur, as I timed the January 2016 low in precious metals stocks very well, and 2016 was one of my best years in the market, right up there with 2009 when I bought tech at the bottom. I still follow the tech/internet space and I plan to eventually jump fully back into that sector, but it's not where my attention is at the moment as I see much better opportunities in gold and silver.
I believe in buying value, and not chasing the next hot stock. I use several basic investing principles, the main one being buying the balance sheet. I wait for opportunities to present themselves and then establish positions. I believe in doing your homework, and I have a very research intensive focus.
*Disclaimer* I am not a Certified Financial Advisor. My research and articles should not be interpreted as a recommendation to purchase, sell, or hold any security at any time. The accuracy, completeness, or timeliness of the information posted in my articles is not guaranteed. Do not rely on any statement that I make in my articles. All readers and subscribers should always conduct their own research and should consult a professional financial advisor when it comes to making investment decisions.
Peter Way Associates provides daily updated, near-term price range forecasts for over 2,000 widely-held and actively-traded stocks, ETFs and market Indexes.__
These are derived from the way market professionals protect their own capital placed at risk while helping big-money portfolio managers adjust their holdings in multi-million-dollar "block" transactions.__
Having these price-change prospects available on a continuous basis encourages individual investors to actively and economically build up the values of their own smaller portfolios. PWA only provides information for individual investors; it no longer manages investments for others.__
Rates of portfolio capital growth being achieved by subscribers are at MULTIPLES of the growth in market averages, due to the efficient use of holding period time and the compounding of gains a number of times each year.__
Risks of capital loss are protected against by insightful selection guidance and holding-period-limit disciplines. The advantages of good selection and careful timing amply cover a much smaller portion of unavoidable losses.__
These Market-maker forecasts have several decades of demonstrated productivity. Earlier in the 20th century they were used by large institutional portfolios, and now in the 21st century they are available only to individual investor wealth-building portfolios. Thousands of day-by-day identifications of specific securities having consistent, odds-on profitable results rule out any likelihood of their exceptional outcomes being due to chance. These price forecasts cannot be found elsewhere.__
Peter F. Way is a veteran Chartered Financial Analyst, having taken and passed the CFA Institute’s required 3 examinations in the first years they were given, 50+ years ago. Armed with BS in Economics from the Wharton School and an MBA degree from Harvard Business School, he has managed staffs of dozens of Investment Researchers and Quantitative Analysts for the nation’s largest bank, arbitraged index options for NYSE Specialists, and managed portfolios of hundred-million-dollar equity investments for Fortune 100 corporate pension funds and non-profit endowments. He has been elected President of professional Investment Analyst Societies in San Diego and New York City and has served on the editorial boards of the Financial Analysts Journal and the CFA Digest.
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
Day trader whose strategy is based on arbitrages in preferred stocks and closed end funds.My group consists of 10 traders.We trade every single preferred stock or closed end fund that provides an arbitrage opportunity. Our research includes stocks that most of the people have not even heard. We have developed our own statistical tools that make most of our arbitrages statistically proven. As a trader I don't just analyse , I trade my analysis and pay the price when I am wrong.That is the main reason I respect opinions only when backed by taking the risk of being wrong.Words or opinions mean nothing in this business and the only person who is right about a certain situation is the one who makes money out of it.
Owen Williams, CFA, DBA, is an equity fund manager in Geneva, Switzerland and a visiting professor at the Skema Business School, Paris, France. Dr. Williams has worked 16 years in the industry as both a bond/economics strategist with a top, independent research boutique and as a long-only macro equity fund manager. He has a Masters degree in international business from the Moore School of Business (Univ. of South Carolina) and a doctorate in finance from the Grenoble Ecole de Management.
Williams Market Analytics, LLC is a quantitative research boutique offering insightful, actionable analysis of financial markets. The firms also runs a systematic allocation strategy using Dr. Williams' quantitative models. The strategy portfolio can be accessed by both individual investors and RIAs in the U.S. and Europe. The strategy description and 5-year performance record can be found at:
Learn more about the Small Cap model portfolio and the Prudent Biotech model portfolio at Graycell Advisors
Besides being an Analyst on both the Buyside and Sellside, the author has worked in Corporate Strategy and Finance roles for technology services companies and has now been publishing risk-adjusted return-driven quantitative model portfolios for many years at Graycell Advisors. More about the author can be learned here.
During 2016, the Graycell Small Cap Portfolio was up +71% compared to benchmark Russell 2000 Index gain of +19%. The Prudent Biotech Portfolio was up +7%, compared to Biotech Index (IBB) decline of -21% in 2016. In 2017, the outperformance continued, and so in 2018. Recent performance numbers are available here for Graycell Advisors and here for Prudent Biotech.
You are invited to take a look at our website for Samples, Performance, Philosophy, and Approach, and decide if the Biotech and Small Cap products can contribute to your investment objectives.
You can even Register for a Free Monthly Pick from the Biotech as well as Small Cap model portfolios.
Any questions, please write to Support @ GraycellAdvisors .com or use the Contact Form.
Graycell Advisors and related entities are not a Registered Investment Advisor (RIA). Nothing here or on the site constitutes a personalized investment recommendation, and stocks mentioned in the reports/articles/comments may be now or in the past, part of the portfolios recommended by Graycell Advisors and related entities. All opinions expressed are subject to change as new information develops, and no updates will be provided on model portfolios unless you are a subscriber. In addition, even though the author may not have a personal position in the stock names discussed, positions in such stocks may exist within related family and associates accounts.
Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
Learning as I go. My investing experience is limited, but I believe that biotechnology/pharmaceuticals hold the key to the best returns in the next 5-10 years. Targeted therapy, monoclonal antibodies, and genetic treatment tailoring are the future of medicine.
I am a practicing Army Physician (Diagnostic Radiologist). My professional interests include neuroradiology, brain tumors, head and neck cancer, functional MRI, and emerging tagged imaging agents. I intend to apply for a fellowship in neuroradiology this coming Summer. As such, I intend my writing to be speculative, but directed by science and my experiences thus far in medicine with an optimistic essence.